The Pulse
The FDA is still weighing large-scale GLP-1 compounding, with a comment window closing June 29.
Back in late April the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulk drug substances list. The public comment period runs through June 29, after which the agency decides.
Worth holding this one loosely. The end of compounded GLP-1 has been called more than once already, through shortage delistings, warning letters, and the Novo settlements, and the supply has kept finding a path each time.
The direction of travel is clearly tighter. The timeline keeps slipping. Treat it as a trend to prepare for, not a date to bet the business on.
On the front end new patients go to branded. The back end is still largely compounded.
Hims settled with Novo Nordisk in March and stopped starting new patients on compounded semaglutide, defaulting signups to branded Wegovy and Zepbound. But existing patients stay on compounded, and that is still where a large share of active books sit.
So the shift to branded is mostly a front-end story so far. The installed base is still largely on compounded, paying the lower price, roughly $79-159 a month against $249-399 for branded.
The interesting retention question is not the new signup. It is what happens to the existing compounded patient if and when their price has to move.
Noom is betting the other direction with low-dose compounded.
Noom expanded its Microdose program, pairing a quarter-dose of compounded semaglutide (0.6mg versus Wegovy’s 2.4mg) with behavioral coaching, from around $79 a month.
While the front-end trend points toward branded, Noom is doubling down on low-dose compounded plus behavior change, leaning on lower side effects and lower price.
Whether it survives the 503B decision is an open question, but the logic is clear: they are competing on the experience around the molecule, not the molecule itself.
The Deep Dive
Every few months someone declares compounded GLP-1 dead. It keeps not dying. But patients still move to branded one at a time, and that switch is where you quietly lose them.
Forget the regulatory timeline for a second. Whatever the FDA decides in June, patients already cross from compounded to branded constantly: a dose change, an insurance shift, a brand moving its own book, a personal choice.
Most brands treat that crossing as an administrative update. “Your medication is changing. Here is your new price.”
That email hands a chunk of your book to whoever is cheaper next month.
A patient who said yes at $159 has not said yes at $399.
The jump from compounded to branded is not a 10% bump. It is 2 to 4 times the monthly cost.
Someone who signed up at $99 or $159 made a specific decision at that number. Branded at $349 is a different offer to a different buyer.
Announce the new price as a fact and you are asking them to re-buy at the higher number with no new reason to. Most will price-shop instead, and right now there is always somewhere cheaper.
The standard “your meds are changing” email loses them because it sells nothing.
A logistics email frames the switch as something happening to the patient. Higher price, same outcome, no upside. That framing only ever loses on price.
The switch has a real story, and almost nobody tells it:
Branded is FDA-approved and consistent-dose, the version with the actual clinical trial data behind it.
It is the one insulated from the next regulatory action, whenever that lands.
It is the one with real insurance and savings-card pathways, which compounded never had.
That is not a price increase. That is an upgrade the patient now qualifies for, told in clinical language, not billing language.
The migration sequence that actually keeps them is built before you need it.
The brands that hold this book do three things the logistics email cannot.
They start the conversation early, not the day a patient’s supply or price changes. The patient hears “your treatment is leveling up” long before they hear a new number.
They pull the plan-length lever. A multi-month or quarterly plan softens the per-month jump and locks commitment at the moment churn risk peaks, and multi-month plans already retain 2 to 3 times better than monthly.
They segment by tenure and results. The patient down 30 pounds gets an identity-and-momentum message. The skeptical month-2 patient gets a different one. A single blast to every compounded patient wastes both.
The takeaway. You do not need to bet on a June 29 outcome to know this switch is coming, patient by patient, one way or another. Build the migration as a real sequence, reframe branded as the upgrade, and have the plan-length offer ready before a price move turns the choice into pay more or leave.
Quick Takes
Noom’s low-dose bet is really a side-effect bet, and side effects are a month-1 churn driver.
Microdosing GLP-1 is being sold on tolerance and price, but the retention read is sharper than that.
The most physically uncomfortable window in GLP-1 is days 15 to 28, when nausea and GI issues peak and patients quit from discomfort they were not prepared for. Lower dose, fewer of those exits.
Whether or not you copy the low-dose model, the lesson holds: the cheapest retention win in weight loss is often pre-empting side effects, not adding another offer.
If your CRM cannot tell compounded patients from branded patients, you cannot message either one properly.
Patients already move between the two formulations one at a time, by dose, by insurance, by choice. The keep-play above depends on a clean property marking which formulation each patient is on, when they started, and when their supply renews.
Most brands do not have that tagged cleanly, because compounded and branded were never separate cohorts until recently. So the migration email goes to everyone or to no one.
Fixing the tag is a 30-minute job. It is basic hygiene now, and it becomes essential the day any larger shift actually lands.
One Thing to Try
Draft your compounded-to-branded migration play now, so it is ready whenever you need it.
Pull every patient currently on compounded semaglutide or tirzepatide. Tag them by tenure and by results so far, even roughly.
Then write one email that reframes branded as the upgrade they qualify for (FDA-approved, consistent dose, insurance pathways) and pairs it with a multi-month plan that cushions the per-month jump.
You do not have to send it this week. You just want it built before you need it, not scrambled together the week a patient’s price moves.
The brands with this ready keep patients through the switch. The brands improvising it send a price increase and watch the book shop around.
If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz
Reply to this with your biggest retention challenge. I read and respond to every single one.